Research Grade Canakinumab (DHB95601)

Catalog No.

DHB95601

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

Interleukin-1 beta, IL1B, Catabolin, IL1F2, IL-1 beta

Concentration

1.94 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P01584

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

ACZ885, CAS: 914613-48-2

Clone ID

Canakinumab

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease, PMID: 28845751

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes, PMID: 29768139

Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study, PMID: 33385581

Canakinumab, PMID: 31643219

Blockage of interleukin-1β with canakinumab in patients with Covid-19, PMID: 33311551

Canakinumab for the treatment of adult-onset Still's disease, PMID: 31957508

Canakinumab, PMID: 20065636

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis, PMID: 23252526

Canakinumab, PMID: 29999640

Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes, PMID: 29544870

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial, PMID: 28855077

Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial, PMID: 32404342

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study, PMID: 32783351

Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure, PMID: 30586730

Canakinumab for the treatment of hyperimmunoglobulin D syndrome, PMID: 30652926

Canakinumab in gout, PMID: 22784099

Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy, PMID: 30832770

Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes, PMID: 30447083

Expedited Desensitization to Canakinumab, PMID: 32612876

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS), PMID: 30165610

Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review, PMID: 32502728

Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases, PMID: 32419407

COVID-19 revisiting inflammatory pathways of arthritis, PMID: 32561873

Canakinumab for secondary prevention of atherosclerotic disease, PMID: 29265905

Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial, PMID: 33023946

Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis, PMID: 32918702

A review of canakinumab and its therapeutic potential for non-small cell lung cancer, PMID: 31503012

Canakinumab for Atherosclerotic Disease, PMID: 29322757

Canakinumab for Atherosclerotic Disease, PMID: 29322754

Canakinumab for Atherosclerotic Disease, PMID: 29322758

Canakinumab for Atherosclerotic Disease, PMID: 29320648

Canakinumab for Atherosclerotic Disease, PMID: 29322756

Canakinumab for Atherosclerotic Disease, PMID: 29322755

The Challenges of Approaching and Managing Gout, PMID: 30447743

Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events, PMID: 30649147

Canakinumab for the treatment of familial Mediterranean fever, PMID: 28362189

Canakinumab: in patients with cryopyrin-associated periodic syndromes, PMID: 22168385

Canakinumab for the treatment of active systemic juvenile idiopathic arthritis, PMID: 27367267

NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis, PMID: 29880500

Canakinumab and Lung Cancer: Intriguing, but Is It Real?, PMID: 29666299

Canakinumab for the treatment of TNF-receptor associated periodic syndrome, PMID: 28454496

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial, PMID: 29146124

Validating canakinumab therapy for autoinflammation, PMID: 29844383

Familial Mediterranean Fever, PMID: 30686512

Macrophage activation syndrome in the era of biologic therapy, PMID: 27009539

Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome, PMID: 31940469

Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study, PMID: 32827729

Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis, PMID: 31463794

Interference of canakinumab with commercial IL-1β ELISAs, PMID: 31096037

Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis, PMID: 25822149

Document Download

Research Grade Canakinumab.pdf